Abstract:To the Editor, The coronavirus disease 2019 (COVID-19) pandemic continues to pose a serious threat to people’s lives, owing to the variants, particularly the B.1.617.2 (delta) variant. We recently published a paper in Molecular Therapy that studies the efficacy and safety of COVID-19 vaccines in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1Cai C. Peng Y. Shen E. Huang Q. Chen Y. Liu P. Guo C. Feng Z. Gao L. Zhang X. Gao Y. et al.A comprehensive analysis of the efficacy and safety of COVID-19 vaccines.Mol. Ther. 2021; 29: 2794-2805Google Scholar Here, we report analyses of the efficacy of COVID-19 vaccines against the delta variant. We evaluated the efficacy of COVID-19 vaccines from the perspective of overall infection, severe infection, and fatal infection, following receipt of 3 types of vaccines: messenger RNA (mRNA)-based vaccine; viral vector (non-replicating) vaccine; and inactivated vaccine (no data have been reported for other types of vaccines). We identified records by searching Google Scholar, PubMed, Medline, Excerpt Medica Database (EMBASE), and the Cochrane Central Register of Controlled Trials (CENTRAL) for “(COVID-19 vaccine), B.1.617.2, and delta variant” on 11 August 2021. They comprised 7 clinical trials, 3 categories of vaccine (comprising 6 different vaccines), and a total of 504,781 cases (69,315 versus 435,466).2Tang P. Hasan M.R. Chemaitelly H. Yassine H.M. Benslimane F.M. Al Khatib H.A. AlMukdad S. Coyle P. Ayoub H.H. Al Kanaani Z. Al Kuwari E. et al.BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar.medRxiv. 2021; https://doi.org/10.1101/2021.08.11.21261885Google Scholar, 3Puranik A. Lenehan P.J. Silvert E. Niesen M.J.M. Corchado-Garcia J. O’Horo J.C. Virk A. Swift M.D. Halamka J. Badley A.D. Venkatakrishnan A.J. et al.Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.medRxiv. 2021; https://doi.org/10.1101/2021.08.06.21261707Google Scholar, 4Lopez Bernal J. Andrews N. Gower C. Gallagher E. Simmons R. Thelwall S. Stowe J. Tessier E. Groves N. Dabrera G. et al.Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant.N. Engl. J. Med. 2021; 385: 585-594Google Scholar, 5Nasreen S. Chung H. He S. Brown K.A. Gubbay J.B. Buchan S.A. Fell D.B. Austin P.C. Schwartz K.L. Sundaram M.E. Calzavara A. et al.Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada.medRxiv. 2021; https://doi.org/10.1101/2021.06.28.21259420Google Scholar, 6Li X.N. Huang Y. Wang W. Jing Q.L. Zhang C.H. Qin P.Z. Guan W.J. Gan L. Li Y.L. Liu W.H. et al.Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.Emerg. Microbes Infect. 2021; 10: 1751-1759Google Scholar, 7Thangaraj J.W.V. Yadav P. Kumar C.G. Shete A. Nyayanit D.A. Rani D.S. Kumar A. Kumar M.S. Sabarinathan R. Kumar V.S. et al.Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021.J. Infect. 2021; (Published online August 5, 2021)https://doi.org/10.1016/j.jinf.2021.08.006Google Scholar, 8Chia P.Y. Xiang Ong S.W. Chiew C.J. Ang L.W. Chavatte J.-M. Mak T.-M. Cui L. Kalimuddin S. Chia W.N. Tan C.W. Chai L.Y.A. et al.Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study.medRxiv. 2021; https://doi.org/10.1101/2021.07.28.21261295Google Scholar A meta-analysis was performed using R statistical software (details are shown in supplemental information, Figure S1, and Table S1).9Belongia E.A. Simpson M.D. King J.P. Sundaram M.E. Kelley N.S. Osterholm M.T. McLean H.Q. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.Lancet Infect. Dis. 2016; 16: 942-951Google Scholar We first investigated the efficacy of COVID-19 vaccines against overall infection by the delta variant. The efficacy was 59% (95% confidence interval [CI]: 26.13; 100) for inactivated vaccines, 67.74% (95% CI: 62.26; 72.53) for viral vector vaccines, and 77.74% (95% CI: 68.22; 88.59) for mRNA-based vaccines (Figures 1A and 1D ). We next evaluated the efficacy against severe infection (defined as per World Health Organization guidelines).2Tang P. Hasan M.R. Chemaitelly H. Yassine H.M. Benslimane F.M. Al Khatib H.A. AlMukdad S. Coyle P. Ayoub H.H. Al Kanaani Z. Al Kuwari E. et al.BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar.medRxiv. 2021; https://doi.org/10.1101/2021.08.11.21261885Google Scholar The efficacy of inactivated vaccines was 70.2% (95% CI: 40.42; 100), of viral vector (non-replicating) vaccines 95% (95% CI: 78.15; 100), and of RNA-based vaccines 89.25% (95% CI: 77.78; 100; Figures 1B and 1D). To further evaluate the efficacy of COVID-19 vaccines against severe infection with delta variant, we compared vaccinated and un-vaccinated patients. Because the clinical trials of viral vector (non-replicating) vaccines lack sufficient numbers of mild and moderate cases and deaths, only mRNA-based vaccines and inactivated vaccines were included in this analysis. The results showed that the incidence of death in the entire vaccinated group was 0%, although the rate in the un-vaccinated group was 1.25%–4.55%. Meanwhile, the incidence of moderate infection in the vaccinated group (6.73%–60%) was lower than that in un-vaccinated group (19.32%–86.37%). The RNA-based vaccines showed better protection than inactivated vaccines (Figures 1C and 1D). In term of efficacy against overall infection by the delta variant, RNA-based vaccines ranked first, followed by viral vector (non-replicating) vaccines and inactivated vaccines, which is consistent with the results against the original SARS-CoV-2 strain. RNA-based vaccines may be more effective against these mutant strains, owing to their complete presentation of the full immunogenicity of SARS-CoV-2. However, the efficacy of all vaccines was decreased against the delta variant. The level of neutralizing antibodies is an important factor in determining the effectiveness of vaccines. For all types of vaccine, the titers of neutralizing antibodies against the delta variant after infection were decreased compared with that of original virus strains.10Chen X. Chen Z. Azman A.S. Sun R. Lu W. Zheng N. Zhou J. Wu Q. Deng X. Zhao Z. et al.Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis.Clin. Infect. Dis. 2021; : ciab646Google Scholar At the same time, some studies have found that the peak of delta virus burden is the same in vaccinated people compared to those who have not been vaccinated.11Pouwels K.B. Pritchard E. Matthews P.C. Stoesser N. Eyre D.W. Vihta K.-D. House T. Hay J. Bell J.I. Newton J.N. Farrar J. et al.Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.medRxiv. 2021; https://doi.org/10.1101/2021.08.18.21262237Google Scholar These findings may explain the reduced effectiveness of the vaccine. Chen et al.10Chen X. Chen Z. Azman A.S. Sun R. Lu W. Zheng N. Zhou J. Wu Q. Deng X. Zhao Z. et al.Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis.Clin. Infect. Dis. 2021; : ciab646Google Scholar found that mRNA-based vaccines produced the highest level of neutralizing antibodies in both normal vaccinated humans and in patients infected with delta variant, which is consistent with the efficacy analysis. However, for viral vector (non-replicating) vaccines and inactivated vaccines, the titers of neutralizing antibodies in vaccinated patients were significantly lower than those in previously infected patients,10Chen X. Chen Z. Azman A.S. Sun R. Lu W. Zheng N. Zhou J. Wu Q. Deng X. Zhao Z. et al.Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis.Clin. Infect. Dis. 2021; : ciab646Google Scholar suggesting that they carry insufficient immunogenicity, resulting in decreased efficacy. Although vaccination cannot completely prevent infection by the COVID-19 delta variant, protection against moderate and severe infection remains satisfactory, and all vaccines exhibit efficacy greater than 70%. The viral vector (non-replicating) vaccines exhibit the highest efficacy, but due to the small sample size, this result is somewhat biased. Vaccination can prevent death, and the proportion of severe cases is also greatly reduced compared to the un-vaccinated. Therefore, vaccination remains an important preventive method for the delta variant. However, a noteworthy problem remains. Whereas the vaccine could prevent moderate and severe infections, the viral burden was unchanged.11Pouwels K.B. Pritchard E. Matthews P.C. Stoesser N. Eyre D.W. Vihta K.-D. House T. Hay J. Bell J.I. Newton J.N. Farrar J. et al.Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.medRxiv. 2021; https://doi.org/10.1101/2021.08.18.21262237Google Scholar This may delay diagnosis to a certain extent and may thus increase the risk of transmission, particularly to un-vaccinated people.12Subbaraman N. How do vaccinated people spread Delta? What the science says.Nature. 2021; 596: 327-328Google Scholar Booster shots may address this problem. Pouwels et al.11Pouwels K.B. Pritchard E. Matthews P.C. Stoesser N. Eyre D.W. Vihta K.-D. House T. Hay J. Bell J.I. Newton J.N. Farrar J. et al.Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.medRxiv. 2021; https://doi.org/10.1101/2021.08.18.21262237Google Scholar comprehensively compared the viral load and neutralizing antibody levels of the various strains among previously infected, vaccinated, and un-vaccinated people. They observed that the risk of infection by the delta variant in previously infected people was lower than in vaccinated people and that the level of neutralizing antibodies in previously infected people was greater than in vaccinated people,11Pouwels K.B. Pritchard E. Matthews P.C. Stoesser N. Eyre D.W. Vihta K.-D. House T. Hay J. Bell J.I. Newton J.N. Farrar J. et al.Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.medRxiv. 2021; https://doi.org/10.1101/2021.08.18.21262237Google Scholar suggesting that antibodies against the original virus strains still play an important role in the control of current variant strains, as do the COVID-19 vaccines. Nevertheless, because efficacy is weakened because of different levels of immunogenicity, booster shots may strengthen protection by the vaccines.13Vogel G. Unethical? Unnecessary? The booster debate intensifies.Science. 2021; 373: 949-950Google Scholar,14Tregoning J.S. Flight K.E. Higham S.L. Wang Z. Pierce B.F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.Nat. Rev. Immunol. 2021; (Published online August 9, 2021)https://doi.org/10.1038/s41577-021-00592-1Google Scholar Some countries have already approved the use of booster shots, with prioritization of the immunocompromised.13Vogel G. Unethical? Unnecessary? The booster debate intensifies.Science. 2021; 373: 949-950Google Scholar Another option is the development of new vaccines; however, the virus that causes COVID-19 mutates almost once a week,15Morales A.C. Rice A.M. Ho A.T. Mordstein C. Mühlhausen S. Watson S. Cano L. Young B. Kudla G. Hurst L.D. Causes and consequences of purifying selection on SARS-CoV-2.Genome Biol. Evol. 2021; (Published online August 24, 2021)https://doi.org/10.1093/gbe/evab196Google Scholar and the rate of vaccine development may be insufficient against this rate of mutation, unless a vaccine with stronger immunogenicity can be developed. Our analysis has some limitations. Due to the limited data for the delta variant and the fact that all studies were test-negative design, researchers have corrected vaccine efficiency for different reasons, which results in a large heterogeneity of the data. In addition, most of the studies are published on pre-printed platforms and have not yet undergone peer review. Thus, there may be design flaws leading to data bias. Therefore, further real-world data are needed for verification. We conclude that the efficacy of all COVID-19 vaccines has dropped against the delta variant. Fortunately, the COVID-19 vaccines exhibit satisfactory efficacy against severe infection. Undoubtedly, vaccination is the most promising means to control COVID-19, including that caused by the delta variant. Nonetheless, the vaccine booster shots should be considered to combat COVID-19 variants. Download .pdf (.17 MB) Help with pdf files Document S1. Supplemental materials and methods and Figure S1 Download .xlsx (.01 MB) Help with xlsx files Table S1. Vaccine efficacy of COVID-19 vaccines

Abstract:Dear editor: Recent articles in this Journal have reported the cross-neutralization of SARS-CoV-2 variants in individuals of vaccinees and convalescents, and compared the clinical features of Coronavirus disease 2019 (COVID-19) by SARS-CoV-2 Gamma variant based on a prospective cohort study of vaccinated and unvaccinated healthcare workers1Gidari A. et al.Cross-neutralization of SARS-CoV-2 B1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.J Infect. 2021; 83: 467-472https://doi.org/10.1016/j.jinf.2021.07.019Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar,2Luna-Muschi A. et al.Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers.J Infect. 2021; https://doi.org/10.1016/j.jinf.2021.09.005Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar. The emergence of SARS-CoV-2 variants with higher transmission ability and immune evasion against monoclonal antibodies, sera from natural infection and vaccine receipts, posing a serious threat to public health. On 26 November 2021, the World Health Organization named the new SARS-CoV-2 variant B.1.1.529 as Omicron, and defined it as a Variant of Concern (VOC). As the fifth VOCs currently, Omicron contains much more mutations in the Spike protein, including some mutations shown to reduce neutralizing efficiencies of COVID-19 vaccines in previous studies3Tao K. et al.The biological and clinical significance of emerging SARS-CoV-2 variants.Nat Rev Genet. 2021; 22: 757-773https://doi.org/10.1038/s41576-021-00408-xCrossref PubMed Scopus (180) Google Scholar. As the pandemic of COVID-19 has lasted for nearly two years, there are more and more convalescents either previously infected with wild-type SARS-CoV-2 or recently emerged variants. Meanwhile, booster vaccination of SARS-CoV-2 is now rapidly rolling out in China and other countries. Accordingly, neutralizing efficiency of convalescents and vaccinees with booster vaccination against the newly emerged Omicron variant needs further elucidation. Here we evaluated the neutralizing activity of plasma from the COVID-19 convalescents with wild type SARS-CoV-2 and different VOCs, and vaccinees with both regular vaccination and homologous booster of inactivated vaccine. A total of 92 participants were included in this study, including 24 vaccinees with homologous booster vaccination (Vaccinee group), 26 individuals previously infected with wild type (WT) SARS-CoV-2 (WT group), 16 patients infected with Alpha variant (Alpha group, 12 patients received vaccination before infection), 6 patients infected with Beta variant (Beta group), and 20 patients infected with Delta variant (Delta group, 4 patients received vaccination before infection). All the individuals with breakthrough infection received at least one-dose inactivated vaccines (CoronaVac or BBIBP-CorV before laboratory confirmation of infection, and individuals in the vaccinee group received inactivated vaccines (BBIBP-CorV) and homologous booster vaccination. The detailed information was shown in Table S1. All the plasma samples in the WT group were collected over 386 days post illness onset/laboratory confirmation (median: 431.5; range: 386–471), and most samples (40/42, 95.23%) in the Alpha, Beta, Delta groups were collected over 7 days after laboratory confirmation (median: 18; range: 1–36). Samples from the vaccinee group were collected after the two dose of vaccination with median days of 85 (range: 28–103), and 95 days after booster vaccination. For the WT group, about 46.15% (12/26) of the samples showed inhibition rates over 50% against Omicron variant at the first dilution (1:20). The geometric mean neutralizing titers (GMTs) against wild type SARS-CoV-2 (WT) and Omicron variant were 154.07 (54.64 to 1018.82), 22.96 (10 to 145.38), respectively, and the reduction fold was 6.71 for Omicron (Fig. 1A). This reduction is comparable with Mu variant while higher than Alpha, Beta, Gamma, Delta, Lambda variants4Yang; Y et al.Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.Nature Mocribiol. 2021; 6Google Scholar. For the Alpha group, all the samples from breakthrough infections showed detectable 50% inhibitory dose (ID50) against Omicron variant, while 50% (2/4) were below the lower limit of quantitation in the naive infections. The overall GMTs against Alpha and Omicron variants were 7198.43 and 285 respectively, with 25.26-fold reduction for the Omicron variant (Fig. 1B). Comparison between breakthrough and naive infection showed significantly higher ID50 against both Alpha (9.33-fold) and Omicron variants (5.61-fold) in the breakthrough infection (Fig. 1B). Similar results were found in the Delta group, with all the samples from breakthrough infection showed detectable ID50 against Omicron variant, while 1 out of 16 was below the lower limit of quantitation in the naive infection. The overall GMTs against Delta and Omicron variants were 10,898.97 and 558.44, respectively, with 19.52-fold reduction for the Omicron variant (Fig. 1D). Significantly higher ID50 against both Delta (3.25-fold) and Omicron variants (1.77-fold) were also found in the breakthrough infections (Fig. 1D). For the Beta group, we only got the naive infections, and reduced neutralizing activities were also found with 18.38-fold reduction against the Omicron variant (Fig. 1C). In the Vaccinee group, 91.66 (22/24) showed detectable ID50 against wild type SARS-CoV-2 at 95 days post booster vaccination with GMT of 299, and 1.67-fold, 14.52-fold, 3.72-fold and 6.73-fold reduction against Alpha, Beta, Gamma and Delta variants were found, respectively (Fig. 2A). Notably, only 25% (6/24) of the samples showed detectable ID50 against Omicron, with 16.07-fold reduction when compared with wild type SARS-CoV-2. We further compared the neutralization activity before and after booster vaccination against different VOCs. After booster vaccination, GMTs against wild type, Alpha, Beta, Gamma, Delta increased 13.47-fold, 8.63-fold, 2.06-fold, 6.75-fold and 3.96 fold, respectively (Fig. 2B). For the Omicron variant, all samples were below the lower limit of quantitation after the first two dose vaccination, similar with previous study5Lu L. et al.Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.Clin Infect Dis. 2021; https://doi.org/10.1093/cid/ciab1041Crossref Google Scholar. However, 6 out of 24 (25%) showed detectable ID50 (GMT: 18.62; range: 10 to 454.4) after booster vaccination, with 1.86-fold increase in GMTs (Fig. 2B). Although some recent studies have showed that Omicron variant could escape from the majority of existing SARS-CoV-2 neutralizing antibodies6Cao Y et al.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.Nature. 2021; 585Google Scholar and vaccine induced immune response5Lu L. et al.Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.Clin Infect Dis. 2021; https://doi.org/10.1093/cid/ciab1041Crossref Google Scholar, our study still provide unique information as follows. Firstly, we addressed whether COVID-19 convalescents previously infected with wild type SARS-CoV-2 could provide protection against Omicron Variant even after one year. Secondly, we used paired samples with both regular vaccination and homologous booster vaccination to evaluated the efficiency of booster vaccination. Thirdly, we compared the neutralizing activities against Omicron variant between breakthrough and naive infections with different VOCs. Similar with previous studies, significant immune evasion was found for Omicron variant both in the convalescents and vaccinees, and the reduction folds was even higher than the previously least susceptible Beta and Mu variants4Yang; Y et al.Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.Nature Mocribiol. 2021; 6Google Scholar,7Uriu K. et al.Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum.N Engl J Med. 2021; 385: 2397-2399https://doi.org/10.1056/NEJMc2114706Crossref PubMed Scopus (51) Google Scholar, suggesting a higher risk of breakthrough infection or reinfection. It is worth noting that plasma samples collected over one year post infection showed lower reduction folds against Omicron variant when compared with other convalescents with different VOCs, which might correlate with the increase in the breadth and potency of SARS-CoV-2 specific antibodies due to the maturation of memory B cells8Muecksch F. et al.Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.Immunity. 2021; 54 (1853-1868.e1857)https://doi.org/10.1016/j.immuni.2021.07.008Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 9Sokal A. et al.Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.Cell. 2021; 184 (1201-1213.e1214)https://doi.org/10.1016/j.cell.2021.01.050Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar, 10Wang Z. et al.Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.Nature. 2021; 595: 426-431https://doi.org/10.1038/s41586-021-03696-9Crossref PubMed Scopus (217) Google Scholar. Despite of the obvious immune evasion, our study also confirmed the importance of vaccination, both regular and booster vaccination. As shown in our study, breakthrough infections developed much higher neutralizing antibodies than the naive infection, both against the infected variant and Omicron variant. Moreover, booster vaccination could significantly increase the neutralizing responses to all the VOCs, although lower neutralizing abilities were found against some VOCs. Therefore, active vaccination still serve as one of the most effective measures to control the pandemic of COVID-19, and new vaccines with higher protective efficiency are also in urgent need. This work was supported by grants from National Natural Science Foundation of China ( 32170936 ), National Science and Technology Major Project ( 2021YFC0863300, 2021YFC2301800 ). The authors wish to thank the biological sample bank of the Shenzhen Third People's Hospital for bio-samples and services provided.

Comparison of Neutralizing Activity between Vaccinated and Unvaccinated Hospitalized COVID-19 Patients Infected with Delta, Omicron BA.1, or Omicron BA.2 Variant

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals

Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing

The Efficacy of COVID-19 Vaccines Against the B.1.617.2 (delta) Variant.

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Impact of Vaccination on Kinetics of Neutralizing Antibodies Against SARS-CoV-2 by Serum Live Neutralization Test Based on a Prospective Cohort

Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2

Regular and Booster Vaccination with Inactivated Vaccines Enhance the Neutralizing Activity Against Omicron Variant Both in the Breakthrough Infections and Vaccinees

Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant

Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID‐19 Booster Vaccines and Recent SARS‐CoV‐2 Omicron Variant Infections

Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis

Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants

Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-Analysis

Comparison of the replication and neutralization of different <scp>SARS‐CoV</scp>‐2 Omicron subvariants in vitro

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

Comparative Neutralisation Profile of SARS-CoV-2 Omicron Subvariants BA.2.75 and BA.5.

Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection